Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin

Cancer Immunity

Volumn 7, Issue , 2007, Pages

  Hassan, Raffit ^a   Ebel, Wolfgang ^b   Routhier, Eric L ^b   Patel, Rina ^b   Kline, J Bradford ^b   Zhang, Jingli ^a   Chao, Qimin ^b   Jacob, Sara ^b   Turchin, Howard ^b   Gibbs, Lester ^b   Phillips, Martin D ^b   Mudali, Shiyama ^c   Iacobuzio Donahue, Christine ^c   Jaffee, Elizabeth M ^c   Moreno, Maria ^d   Pastan, Ira ^a   Sass, Philip M ^b   Nicolaides, Nicholas C ^b   Grasso, Luigi ^b,e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Morphotek Inc   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e NONE   (United States)

Author keywords

Antibody dependent cellular cytotoxicity; Mesothelin; Monoclonal antibody; Preclinical drug evaluation

Indexed keywords

CHIMERIC ANTIBODY; MESOTHELIN; MONOCLONAL ANTIBODY; MORAB 009; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL ADHESION; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MESOTHELIOMA; MOUSE; NONHUMAN; NUDE MOUSE; OVARY ADENOCARCINOMA; PANCREAS ADENOCARCINOMA; SYSTEMATIC REVIEW; TUMOR CELL;

EID: 37449006756     PISSN: None     EISSN: 14249634     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996; 93: 136-140.
2. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004; 10: 3937-3942.
3. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, Murugesan SR, Leach SD, Jaffee E, Yeo CJ, Cameron JL, Kern SE, Hruban RH. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001; 7: 3862-3868.
4. Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, Brackett D. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol 2005; 124: 838-845.
5. Ordonez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003; 16: 192-197.
6. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 1992; 50: 373-381.
7. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003; 27: 1418-1428.
8. Hassan R, Kreitman RJ, Pastan I, Willingham MC. Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol 2005; 13: 243-247.
9. Ho M, Bera TK, Willingham MC, Onda M, Hassan R, FitzGerald D, Pastan I. Mesothelin expression in human lung cancer. Clin Cancer Res 2007; 13: 1571-1575.
10. Miettinen M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol 2003; 27: 150-158.
11. Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 2004; 279: 9190-9198.
12. Bera TK, Pastan I. Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol 2000; 20: 2902-2906.
13. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham M, Pastan I. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin for targeted therapy of mesothelin expressing mesotheliomas, ovarian and pancreatic cancer [meeting abstract]. J Clin Oncol 2007; 25: 3553.
14. Thomas AM, Santarsiero LM, Lutz ER, Armstrong TD, Chen YC, Huang LQ, Laheru DA, Goggins M, Hruban RH, Jaffee EM. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 2004; 200: 297-306.
15. Nicolaides NC, Sass PM, Grasso L. Monoclonal antibodies: a morphing landscape for therapeutics. Drug Dev Res 2006; 67: 781-789.
16. Chowdhury PS, Viner JL, Beers R, Pastan I. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci U S A 1998; 95: 669-674.
17. Chowdhury PS, Pastan I. Analysis of cloned Fvs from a phage display library indicates that DNA immunization can mimic antibody response generated by cell immunizations. J Immunol Methods 1999; 231: 83-91.
18. Fransson J, Borrebaeck CA. The nuclear DNA repair protein Ku70/80 is a tumor-associated antigen displaying rapid receptor mediated endocytosis. Int J Cancer 2006; 119: 2492-2496.
19. Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, Bera TK, Connor J, Sathyanarayana BK, Lee B, Pastan I, Patankar MS. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 2006; 5: 50.
20. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7: 987-989.
21. Holden SA, Lan Y, Pardo AM, Wesolowski JS, Gillies SD. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents. Clin Cancer Res 2001; 7: 2862-2869.
22. Miers L, Lamborn K, Yuan A, Richman C, Natarajan A, DeNardo S, DeNardo G. Does paclitaxel (Taxol) given after (111)In-labeled monoclonal antibodies increase tumor-cumulated activity in epithelial cancers? Clin Cancer Res 2005; 11: 7158s-7163s.
23. Jaffee EM, Schutte M, Gossett J, Morsberger LA, Adler AJ, Thomas M, Greten TF, Hruban RH, Yeo CJ, Griffin CA. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J Sci Am 1998; 4: 194-203.
24. Embuscado EE, Laheru D, Ricci F, Yun KJ, de Boom Witzel S, Seigel A, Flickinger K, Hidalgo M, Bova GS, Iacobuzio-Donahue CA. Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol Ther 2005; 4: 548-554.